Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV1-CB-hAAT in Alpha-1 Antitrypsin Deficiency
NCT01054339Phase 2Completed
- Sponsor
- Beacon Therapeutics
- Start
- Jun 2010
- Primary completion
- Oct 2011
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of rAAV1-CBA-hAAT in alpha-1 antitrypsin deficiency (AATD), sponsored by Beacon Therapeutics. Started Jun 2010; status: completed.
02
Drugs
rAAV1-CBA-hAAT
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT01054339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01054339.